Multicenter, Double-Masked, Randomized, Safety and Efficacy Study of BRIMOCHOL™ PF and Carbachol PF Topical Ophthalmic Solution With Emmetropic Phakic and Pseudophakic Presbyopia

Last updated: November 1, 2023
Sponsor: Visus Therapeutics
Overall Status: Active - Recruiting

Phase

3

Condition

Presbyopia

Treatment

N/A

Clinical Study ID

TX322034
  • Ages 45-80
  • All Genders

Study Summary

Safety and Efficacy Study of BRIMOCHOL™ PF and Carbachol PF in Subjects With Emmetropic Phakic and Pseudophakic Presbyopia

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Male or female in good general health
  • Must have presbyopia

Exclusion

Exclusion Criteria:

  • History of allergic reaction to the study drug or any of its components
  • Any disease or medical condition that, in the opinion of the Investigator, would prevent the subject from participating in the study or might confound study results

Study Design

Study Start date:
Estimated Completion Date:

Study Description

Multicenter, Double-Masked, Randomized, Safety and Efficacy Study of BRIMOCHOL™ PF and Carbachol PF Topical Ophthalmic Solution With Emmetropic Phakic and Pseudophakic Presbyopia

Connect with a study center

  • Connecticut Eye Consultants, P.C.

    Danbury, Connecticut 06810
    United States

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.